<DOC>
	<DOC>NCT02333773</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Portal venous tumor emboli.</brief_summary>
	<brief_title>Irreversible Electroporation(IRE) For Unresectable Portal Venous Tumor Emboli</brief_title>
	<detailed_description>By enrolling patients with unresectable Portal venous tumor emboli adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous or intraoperative IRE for unresectable Portal venous tumor emboli.</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<criteria>Liver cancer diagnosed by positive biopsy or noninvasive criteria, Liver cancer with Portal venous tumor emboli, Not suitable for surgical resection or transplantation, ChildPugh class A,B Eastern Cooperative Oncology Group (ECOG) score of 01, A prothrombin time ratio &gt; 50%, Platelet count &gt; 80x10^9/L, Ability of patient to stop anticoagulant and antiplatelet therapy for seven days prior to and seven days post NanoKnife procedure, Able to comprehend and willing to sign the written informed consent form (ICF), Have a life expectancy of at least 3 months. Cardiac insufficiency, ongoing coronary artery disease or arrhythmia, Any active implanted device (eg Pacemaker), Women who are pregnant or women of childbearing potential who are not using an acceptable method of contraception, Have received treatment with an investigational agent/ procedure within 30 days prior to treatment with the NanoKnifeâ„¢ LEDC System, Are in the opinion of the Investigator unable to comply with the visit schedule and protocol evaluations.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>irreversible electroporation</keyword>
	<keyword>Portal venous tumor emboli</keyword>
</DOC>